Rapamycin, but Not Resveratrol or Simvastatin, Extends Life Span of Genetically Heterogeneous Mice

Overview

Journal J Gerontol A Biol Sci Med Sci

Specialty Geriatrics

Date 2010 Oct 27

PMID 20974732

Citations 522

Authors

Richard A Miller

David E Harrison

C M Astle

Joseph A Baur

Angela Rodriguez Boyd

Rafael de Cabo

Elizabeth Fernandez

Kevin Flurkey

Martin A Javors

James F Nelson

Carlos J Orihuela

Scott Pletcher

Zelton Dave Sharp

David Sinclair

Joseph W Starnes

J Erby Wilkinson

Nancy L Nadon

Randy Strong

Affiliations

Soon will be listed here.

Abstract

Rapamycin was administered in food to genetically heterogeneous mice from the age of 9 months and produced significant increases in life span, including maximum life span, at each of three test sites. Median survival was extended by an average of 10% in males and 18% in females. Rapamycin attenuated age-associated decline in spontaneous activity in males but not in females. Causes of death were similar in control and rapamycin-treated mice. Resveratrol (at 300 and 1200 ppm food) and simvastatin (12 and 120 ppm) did not have significant effects on survival in male or female mice. Further evaluation of rapamycin's effects on mice is likely to help delineate the role of the mammalian target of rapamycin complexes in the regulation of aging rate and age-dependent diseases and may help to guide a search for drugs that retard some or all of the diseases of aging.

Citing Articles

The Potential of Polyphenols in Modulating the Cellular Senescence Process: Implications and Mechanism of Action.

Della Vedova L, Baron G, Morazzoni P, Aldini G, Gado F Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40005954 PMC: 11858549. DOI: 10.3390/ph18020138.

Test of Rapamycin in Aging Dogs (TRIAD): study design and rationale for a prospective, parallel-group, double-masked, randomized, placebo-controlled, multicenter trial of rapamycin in healthy middle-aged dogs from the Dog Aging Project.

Coleman A, Creevy K, Anderson R, Reed M, Fajt V, Aicher K Geroscience. 2025; .

PMID: 39951177 DOI: 10.1007/s11357-024-01484-7.

Enhancing immunity during ageing by targeting interactions within the tissue environment.

Bracken O, De Maeyer R, Akbar A Nat Rev Drug Discov. 2025; .

PMID: 39875569 DOI: 10.1038/s41573-024-01126-9.

A Review of Telomere Attrition in Cancer and Aging: Current Molecular Insights and Future Therapeutic Approaches.

Iskandar M, Xiao Barbero M, Jaber M, Chen R, Gomez-Guevara R, Cruz E Cancers (Basel). 2025; 17(2).

PMID: 39858038 PMC: 11764024. DOI: 10.3390/cancers17020257.

Mikhail 'Misha' Blagosklonny's enduring legacy in geroscience: the hyperfunction theory and the therapeutic potential of rapamycin.

Barzilai D Aging (Albany NY). 2025; 17(1):1-15.

PMID: 39808121 PMC: 11810056. DOI: 10.18632/aging.206189.

References

Bauer J, Goupil S, Garber G, Helfand S . An accelerated assay for the identification of lifespan-extending interventions in Drosophila melanogaster. Proc Natl Acad Sci U S A. 2004; 101(35):12980-5. PMC: 516504. DOI: 10.1073/pnas.0403493101. View

Haendeler J, Hoffmann J, Diehl J, Vasa M, Spyridopoulos I, Zeiher A . Antioxidants inhibit nuclear export of telomerase reverse transcriptase and delay replicative senescence of endothelial cells. Circ Res. 2004; 94(6):768-75. DOI: 10.1161/01.RES.0000121104.05977.F3. View

Caccamo A, Majumder S, Richardson A, Strong R, Oddo S . Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. J Biol Chem. 2010; 285(17):13107-20. PMC: 2857107. DOI: 10.1074/jbc.M110.100420. View

Kaeberlein M, McVey M, Guarente L . The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev. 1999; 13(19):2570-80. PMC: 317077. DOI: 10.1101/gad.13.19.2570. View

Verma S, Rao V, Weisel R, Li S, Fedak P, Miriuka S . Novel cardioprotective effects of pravastatin in human ventricular cardiomyocytes subjected to hypoxia and reoxygenation: beneficial effects of statins independent of endothelial cells. J Surg Res. 2004; 119(1):66-71. DOI: 10.1016/j.jss.2003.10.011. View

Kaeberlein M, Kennedy B . Ageing: A midlife longevity drug?. Nature. 2009; 460(7253):331-2. DOI: 10.1038/460331a. View

Mahalingam D, Sankhala K, Mita A, Giles F, Mita M . Targeting the mTOR pathway using deforolimus in cancer therapy. Future Oncol. 2009; 5(3):291-303. DOI: 10.2217/fon.09.9. View

Sharp Z, Bartke A . Evidence for down-regulation of phosphoinositide 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR)-dependent translation regulatory signaling pathways in Ames dwarf mice. J Gerontol A Biol Sci Med Sci. 2005; 60(3):293-300. DOI: 10.1093/gerona/60.3.293. View

Martin D, Hall M . The expanding TOR signaling network. Curr Opin Cell Biol. 2005; 17(2):158-66. DOI: 10.1016/j.ceb.2005.02.008. View

10.

Mita M, Mita A, Rowinsky E . The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. Cancer Biol Ther. 2003; 2(4 Suppl 1):S169-77. View

11.

Assmus B, Urbich C, Aicher A, Hofmann W, Haendeler J, Rossig L . HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ Res. 2003; 92(9):1049-55. DOI: 10.1161/01.RES.0000070067.64040.7C. View

12.

Wang C, Li Q, Redden D, Weindruch R, Allison D . Statistical methods for testing effects on "maximum lifespan". Mech Ageing Dev. 2004; 125(9):629-32. DOI: 10.1016/j.mad.2004.07.003. View

13.

Mita M, Sankhala K, Abdel-Karim I, Mita A, Giles F . Deforolimus (AP23573) a novel mTOR inhibitor in clinical development. Expert Opin Investig Drugs. 2008; 17(12):1947-54. DOI: 10.1517/13543780802556485. View

14.

Spilman P, Podlutskaya N, Hart M, Debnath J, Gorostiza O, Bredesen D . Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PLoS One. 2010; 5(4):e9979. PMC: 2848616. DOI: 10.1371/journal.pone.0009979. View

15.

Kapahi P, Zid B, Harper T, Koslover D, Sapin V, Benzer S . Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway. Curr Biol. 2004; 14(10):885-90. PMC: 2754830. DOI: 10.1016/j.cub.2004.03.059. View

16.

Meric-Bernstam F, Gonzalez-Angulo A . Targeting the mTOR signaling network for cancer therapy. J Clin Oncol. 2009; 27(13):2278-87. PMC: 2738634. DOI: 10.1200/JCO.2008.20.0766. View

17.

Brown-Borg H, Borg K, Meliska C, Bartke A . Dwarf mice and the ageing process. Nature. 1996; 384(6604):33. DOI: 10.1038/384033a0. View

18.

Chen C, Liu Y, Liu Y, Zheng P . mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells. Sci Signal. 2009; 2(98):ra75. PMC: 4020596. DOI: 10.1126/scisignal.2000559. View

19.

Rogina B, Helfand S . Sir2 mediates longevity in the fly through a pathway related to calorie restriction. Proc Natl Acad Sci U S A. 2004; 101(45):15998-6003. PMC: 528752. DOI: 10.1073/pnas.0404184101. View

20.

Stanfel M, Shamieh L, Kaeberlein M, Kennedy B . The TOR pathway comes of age. Biochim Biophys Acta. 2009; 1790(10):1067-74. PMC: 3981532. DOI: 10.1016/j.bbagen.2009.06.007. View